Improvement in school absence after factor replacement in students with haemophilia in Upper Assam, India

Anupam Dutta, Dipjyoti Boruah, Taniya Sarkar Dutta, Angshuman Boruah, Bhabani Shankar Dhal

Background: Patients with haemophilia who are not adequately treated experience a lifetime burden of joint complications and loss of functional ability due to repeated bleeding episodes caused by low levels of clotting factor VIII or IX in the blood. These complications can significantly impact day-to-day life, including active participation in school and academic study in children with haemophilia (CwH). Treatment with factor replacement therapy can help to prevent this, but access to factor has been challenging in low-resource settings such as Northeast India. This study shows the impact of factor replacement therapy on bleeding episodes, joint complications and school absence among CwH in this setting. Methods: A retrospective observational study was undertaken to examine the impact of receiving regular factor replacement therapy (prophylaxis or on demand) on school absences among CwH registered with the haemophilia treatment centre at Assam Medical College and Hospital. Annual bleed rate (ABR), Haemophilia Joint Health Score (HJHS) and Functional Independence Score in Haemophilia (FISH) were also assessed. Results: Thirty-eight CwH were eligible for the study; 26 (68.4%) were on prophylaxis therapy and 12 (31.5%) received on-demand therapy. In the year before starting regular treatment, the mean ABR was 37.8 (+20.0), HJHS was 31.1 (+18.1) and mean FISH score was 21.1 (+4.2). At the end of the study period the mean (+SD) ABR in prophylactic therapy was 14.4 (+10.9), HJHS was 45.4 (+15.7) and mean FISH score was 31.6 (+3.9).
was significantly lower at 5.8 (+4.6) (p<0.001) and the HJHS was significantly lower at 4.7 (+4.6). FISH score significantly improved to 27.9 (+3.3) (p<0.001). Prophylaxis showed better (but not significant) results in comparison to on-demand therapy. Conclusions: Treatment with factor replacement significantly reduces school absence in CwH and correlates strongly with joint health and functional improvement, with the effect slightly better with prophylaxis than on-demand therapy. Low dose prophylaxis is a good treatment option in low-resource settings, but improvements are also needed in rates of diagnosis.

Keywords: Haemophilia, school absence, factor replacement therapy, prophylaxis, on-demand therapy, Northeast India

Haemophilia, an X-linked bleeding disorder, is characterised by reduced levels of coagulation factor VIII (FVIII) or factor IX (FIX) in haemophilia A and B respectively. People with haemophilia (PwH) suffer from repeated bleeding episodes in to joints and muscles that can lead to long-term musculoskeletal complications including conditions such as synovitis, degenerative arthropathy and physical impairment [3]. The frequency of bleeding depends on the residual coagulation factor level and the genotype of the patient [2]. PwH are classified as having severe, moderate or mild haemophilia based on clotting factor levels <1%, 1-5% and 5–40% of normal, respectively [14]. The standard of care recommended by the World Federation of Hemophilia (WFH) is treatment with factor replacement therapy to prevent or treat bleeds, and to make joint damage less likely in the future [5]. This is usually according to the Malmö protocol in which factor concentrate of 25–40 IU/kg is administered three times a week for those with haemophilia A and twice a week for those with haemophilia B, or the Utrecht protocol, where factor concentrates of 15–30 IU/kg is administered three times a week for those with haemophilia A and twice a week for those with haemophilia B. In countries with significant resource constraints, lower doses of prophylaxis may be an effective option. Clotting factor concentrate, an orphan drug [6], is the preferred treatment option, although cryoprecipitate or fresh frozen plasma are also used to treat haemorrhagic episodes [4,7–10]. Treatment with replacement therapy at the time of haemorrhage is known as on-demand therapy; regular infusions of coagulation factor replacement to prevent haemorrhages is known as prophylaxis.

Bleeding episodes and their complications can affect the physical, psychological and social wellbeing of PwH and haemophilia is considered as a significant lifetime burden due to its impact on health-related quality of life (HRQoL) [2,11]. Absence from school is an important HRQoL issue for children with haemophilia (CwH). Frequent absences from school or colleges can result in reduced educational opportunities which later on may impact graduation and employment opportunities and produce low self-esteem. Reports in the literature document higher rates of school absence in children with haemophilia than others [15–16].

Historically, haemophilia has been underdiagnosed in India due to lack of awareness, poor diagnostic facilities and limited registry data [17]. Factor concentrates are costly, and both on-demand and prophylactic treatment can be inaccessible due to issues of availability and affordability. Assam is a state in Northeast India, situated south of the Eastern Himalayas. Its economy is predominantly agriculture-based, and the majority of the population live in rural areas. PwH in the region are treated at Assam Medical College and Hospital (AMCH), which serves upper Assam and areas in the neighbouring states of Arunachal Pradesh and Nagaland. Factors were made available to the AMCH haemophilia treatment centre (HTC) by the WFH via Humanitarian Aid from January 2017 and by the Government of Assam from June 2018. Following this, PwH attending the centre, who had mostly not been on any factor replacement therapy until this time, were informed about prophylaxis and registered with the HTC for factor replacement treatment. Those who agreed to try prophylaxis were initially started on plasma-derived factor concentrate at a low dose of 10 IU/kg once a week for one month to see whether they were compliant and motivated enough to continue prophylaxis. Once they started attending the HTC regularly, the dose was increased to 10–15 IU/kg twice a week for those with haemophilia A, and 15–20 IU/kg once a week for those with haemophilia B [18]. Doses were subsequently tailored individually after clinical assessment. Some patients discontinued or did not consent to prophylaxis but continued to attend the HTC for on-demand treatment.

A number of those recently registered for factor replacement treatment at AMCH HTC are of school- or college-going age. The objective of the study reported here was to assess impact of access to factor replacement therapy, either prophylaxis or on-demand, on school absences.
**METHODS**
This was a single centre, retrospective, questionnaire based, cross-sectional observational study.

**Study participants**
Persons diagnosed with haemophilia A or B, within the age group 6 to 21 years, continuing their studies at school or college, and receiving factor replacement treatment, either prophylaxis or on demand, at AMCH HTC were included in the study. CwH who had finished their education or dropped out of school were excluded.

**Recruitment**
Participants were recruited from the database of the AMCH HTC and contacted via telephone. Those who were eligible for inclusion were asked to take part in a questionnaire-based interview. Informed consent was obtained from parents/guardians or patients as approved by the Institutional Ethical Committee of Assam Medical College.

**Data collection**
Participants were assessed using a questionnaire. Data was captured on their haemophilia type and severity, history of factor consumption, type of factor used, duration of factor used, and treatment as prophylaxis or on-demand therapy. Data on the number of days absent per month in the years before and after enrolment for treatment at AMCH HTC were collected from parents/guardians and the participants. Parents were asked to recollect the number of days their child was absent from school due to haemophilia complications, such as a joint bleed or continuous bleeding due to injury. Absences from school due to other reasons were not counted.

Detailed data on physical examination, annual bleed rate (ABR), annual joint bleed rate (AJBR), Haemophilia Joint Health Score (HJHS) and Functional Independence Score in Haemophilia (FISH) for functional ability were collected from participants’ HTC records from their date of enrolment. The recorded date of joining the HTC provided individual timelines demarcating the period before and after treatment.

**Statistical methods**
Data were presented in Mean (+SD). Pearson correlation was used to show the correlation between school absences and number of bleeding episodes, FISH and HJHS and type of treatment (on-demand or

| VARIABLE                        | PROPHYLAXIS MEAN (±SD) | ON-DEMAND MEAN (±SD) |
|--------------------------------|------------------------|-----------------------|
| Age at enrolment (years)       | 13.1(±4.5)             | 11.7(+4.5)            |
| Duration of prophylaxis (years)| 1.4(+0.2)              | –                     |

**Haemophilia type**
- Haemophilia A: 21
- Haemophilia B: 5

| VARIABLE                        | BEFORE ENROLMENT MEAN (±SD) | AFTER ENROLMENT MEAN (±SD) | P-VALUE*  |
|--------------------------------|----------------------------|-----------------------------|-----------|
| Number of days absent (prophylaxis) | 15(+6)                    | 4(+3)                       | <0.001    |
| Number of days absent (on-demand)   | 10(+5)                    | 3(+2)                       | 0.477     |

**Scores during prophylaxis**
- ABR: 37.8(+20.0) vs 5.8(+4.6) <0.001
- HJHS: 31.1(+18.1) vs 4.7(+4.6) <0.001
- FISH: 21.4(+4.2) vs 27.9(+3.3) <0.001

**Scores during on-demand treatment**
- ABR: 25.5(+19.9) vs 8.7(+6.2) 0.006
- HJHS: 13.8(+11.4) vs 3.1(+4.2) 0.002
- FISH: 24.6(+4.5) vs 29.1(+2.6) <0.001

*p-value calculated by paired t test
prophylaxis). Student t-test was used to compare number of days absent in a month, ABR, HJHS and FISH in prophylaxis and on-demand groups before and after enrolment with the HTC for factor replacement treatment.

RESULTS
Of the 79 patients registered for factor replacement treatment at AMCH HTC, 46 met the age criteria for the study. Five were no longer attending or had dropped out of school and were excluded from the study. A further three were treatment naïve and were also excluded from the study.

Of the 38 CwH who were eligible for the study, 26 (68.4%) were on prophylaxis and 12 (31.5%) received on-demand therapy. The mean age of the participants was 13.1 (+4.5) years in the case of prophylactic treatment, and 11.7 (+4.5) years for on-demand treatment. For those receiving prophylactic treatment, the mean duration of treatment was 1.4 (+ 0.2) years (Table 1).

The number of days absent from school in a month was significantly reduced among the participants who had enrolled into prophylaxis therapy, from an average of 15 before enrolment to four after enrolment (Table 2). A reduction in days of absence was also seen in the on-demand treatment group, from 10 before enrolment to three after enrolment; however, due to the lesser number of participants in this group the reduction was not statistically significant. Similarly, ABR and HJHS were found to be significantly less in CwH now receiving prophylaxis, while the FISH score was significantly higher, indicating an improvement in their functional ability. There were also significantly higher FISH scores in the group receiving on-demand treatment. ABR and HJHS showed improvement in the on-demand treatment group, but not significant at p<0.001.

Both ABR and HJHS were positively correlated with school absence for CwH on prophylaxis (Table 3). Although the HJHS showed a positive correlation with school absence after the introduction of prophylactic treatment, no significant difference could be seen. In the case of on-demand treatment, the HJHS before and after enrolment for treatment showed a positive correlation with school absence but was not significant. The FISH score showed a negative correlation in both prophylaxis and on-demand treatment.

DISCUSSION
Several studies have shown higher levels of absence from school in CwH than in their non-affected classmates and lower academic performance/actual achievement relative to potential [13-16]. Frequent bleeding episodes have a significant impact on school attendance. Shapiro et al. found that the number of bleeding episodes was found to be positively correlated with school absences (Spearman correlation 0.23) and that excessive absences from school resulted in lower levels of academic achievement [19]. Children with fewer bleeding episodes have also been shown to have better PFS (Physical Functioning Scale) scores than children with high levels of bleeding episodes, which can similarly impact on the child’s ability to fulfil their potential during school and later in life [19]. The current study demonstrated a statistically significant improvement in the ABR after school-aged children were enrolled with AMCH HTC and began having treatment with prophylaxis or on-demand treatment as needed, with a corresponding reduction in the number of absences from school. Prophylactic treatment has been shown to minimise both the bleeding episodes and HJHS score, increasing the FISH score [20], which was also seen in the current study.

|                      | BEFORE ENROLMENT | P-VALUE | AFTER ENROLMENT | P-VALUE |
|----------------------|------------------|---------|-----------------|---------|
| **Prophylaxis**      |                  |         |                 |         |
| ABR                  | 0.514            | 0.009   | 0.639           | <0.001  |
| HJHS                 | 0.325            | 0.112   | 0.156           | 0.446   |
| FISH                 | -0.751           | <0.001  | -0.694          | <0.001  |
| **On-demand**        |                  |         |                 |         |
| ABR                  | 0.874            | <0.001  | 0.396           | 0.203   |
| HJHS                 | 0.690            | 0.013   | 0.197           | 0.539   |
| FISH                 | -0.798           | 0.002   | -0.580          | 0.048   |

p-value calculated by Pearson correlation
Figure 1. Correlation of ABR, HJHS and FISH with days of absence during prophylaxis and on-demand treatment

Key: Initial values Final values
The main physical problems for CwH are not external cuts or wounds, but repeated bleeding into joints that can lead to painful, crippling and permanent damage [13]. Factor replacement therapy can significantly reduce bleeding frequency and improve joint and functional scores, which in turn impacts on HRQoL. Currently, challenges exist for implementation of this effective treatment in resource-poor nations where the cost of factor treatment can be prohibitive. However, low dose prophylaxis (LDP) is an option that is relevant and more achievable in low-resource settings and can help to minimise these challenges and to provide better care. Although the aim of prophylaxis is to raise clotting factor levels and keep them at 1% or higher at all times, it is shown to be beneficial even when factor levels are not maintained at this level all the time [21]. Data on LDP in low-resource settings has become available in recent years and shows that it can help reduce the number of bleeding episodes and the associated long-term issues with joint health experienced by PwH [22-25]. LDP is recommended by the Indian Academy of Pediatrics [26] and is also the standard of care for low resource settings recommended by the WFH [40]. Therapeutic care programmes involving LDP can help children with haemophilia in academic achievement by lowering bleeding complications and the number of days when they are from school and help them to actively participate in school and social functions.

Alongside this, however, there is a need to improve diagnosis of haemophilia in India. The latest Indian data published in the WFH Annual Global Survey shows a significant increase (79.3%) in the number of people known to have haemophilia, from 11,586 in 2011 to 20,778 in 2018 [27,28]. However, estimates based on population data in comparison with haemophilia prevalence in countries with higher rates of diagnosis and better developed registries suggest that the actual number of PwH in India is likely to be in excess of 70,000 [29]. Epidemiological data published by the Haemophilia Federation of India (HFI) indicates that Northeast India has a total of 370 registered cases, but the expected number is much higher [29].

CONCLUSION

Factor replacement, in the form of prophylaxis or on-demand therapy, significantly reduces absences from school among CwH. The effect may be slightly better with prophylaxis, but benefit is seen in all types of therapy with factor replacement. This has a huge impact on the lives of the children affected and positively correlates with improvements in bleed rates, joint health scores and functional assessment. LDP in particular has a significant role to play in improving the lives of CwH in India and enabling them to fulfil their potential as they become adults. However, diagnosis of haemophilia in India also needs to be improved in order for this treatment protocol to benefit a greater number of those affected by the disease.

ACKNOWLEDGEMENTS

We are thankful to all the members of Haemophilia Society Tinsukia Chapter for their help, and the Department of Medicine, Paediatrics and Blood Bank at Assam Medical College and Hospital for assisting in running our Haemophilia Treatment Centre, where this study was conducted.

The authors have advised no interests that might be perceived as posing a conflict or bias.

Informed consent has been obtained from the participants in the study reported in this paper.

ORCID

Anupam Dutta https://orcid.org/0000-0001-9520-5196
Dipjoyti Boruah https://orcid.org/0000-0002-6794-815X
Taniya Sarkar Dutta https://orcid.org/0000-0002-1739-2034
Angshuman Boruah https://orcid.org/0000-0001-7063-5085
Bhabani Shankar Dhal https://orcid.org/0000-0003-2272-4395

REFERENCES

1. Rodriguez-Merchan EC. Prevention of the musculoskeletal complications of hemophilia. Adv Prev Med 2012; 2012: 201271. doi: 10.1155/2012/201271.
2. Van den Berg HM, Fisher K. Phenotypic-genotypic relationship. In: Lee CA, Berntorp EE, Hoots WK (ed.). Textbook of Haemophilia. 2nd ed. Chicester: Wiley-Blackwell, 2010: 33-7.
3. Berntorp E, Shapiro AD. Modern haemophilia care. Lancet 2012; 379: 1447-56. doi: 10.1016/S0140-6736(11)61139-2.
4. Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet 2003; 361: 1801-9. doi: 10.1016/S0140-6736(03)13405-8.
5. Srivastava A, Santagostino E, Dougall A. et al. WFH guidelines for the management of haemophilia, 3rd edition. Haemophilia 2020; 00: 1-158. doi: 10.1111/hae.14046.
6. EURORDIS Rare Diseases Europe. About orphan drugs. Available from http://www.eurordis.org/about-orphan-drugs. (accessed 28 September 2020).
7. Mannucci PM. Back to the future: a recent history of haemophilia treatment. Haemophilia 2008; 14(Suppl 3): 10-18. doi: 10.1111/j.1365-2516.2008.01708.x.
8. Franchini M. The modern treatment of haemophilia: a narrative review. Blood Transfus 2013; 11(2): 178-82. doi: 10.2450/2012.0166-11.
9. Carcao MD. The diagnosis and management of congenital hemophilia. Semin Thromb Hemost 2012; 38(7): 727-34. doi: 10.1055/s-0032-1326786.
10. Keeling D, Tait C, Makris M. Guideline on the selection and use of therapeutic products to treat haemophilia and other
hereditary bleeding disorders. A United Kingdom Haemophilia Center Doctors’ Organisation (UKHCDO) guideline approved by the British Committee for Standards in Haematology. Haemophilia 2008; 14(4): 671-84. doi: 10.1111/j.1365-2516.2008.01695.x.

11. Kodra Y, Cavazza M, Schieppati A, et al. The social burden and quality of life of patients with haemophilia in Italy. Blood Transfus 2014; 12(Suppl 3): s567-75. doi:10.2450/2014.0042-14s.

12. Hennard S, Devleesschauwer B, Beutels P, et al. The health and economic burden of haemophilia in Belgium: a rare, expensive and challenging disease. Orphanet J Rare Dis 2014; 9: 39. doi:10.1186/1750-1172-9-39.

13. Markova I, McDonald K, Forbes C. Integration of hemophilic boys into normal schools. Child Care Health Dev 1980; 6: 101-109. doi:10.1111/j.1365-2214.1980.tb00802.x.

14. Woolf A, Rappaport L, Reardon P, Cibrorowski J, D’Angelo E, Besette J. School functioning and disease severity in boys with hemophilia. J Dev Behav Pediatr 1989; 10: 81-85. doi:10.1097/00004703-198904000-00004.

15. Olch D. Effects of hemophilia upon intellectual growth and academic achievement. J Genet Psychol 1971; 119: 63-74. doi:10.1080/00221325.1971.10532627.

16. Colgrove RW, Huntzinger RM. Academic, behavioral, and social adaptation of boys with hemophilia/HIV disease. J Pediatr Psychol 1994; 19(4): 457-73. doi:10.1093/jpepsy/19.4.457.

17. John MJ, Tanuja T, Mathew A, et al. Demographic profile and real world data of persons with hemophilia in a resource constrained setup. CHRISMED Journal of Health and Research 2018; 5: 214-20. doi:10.4103/cjhr.cjhr_44_18.

18. Dutta A, Kakati S, Kar S, Doley D. Joint and functional assessment following secondary and tertiary prophylaxis in people with hemophilia who were previously receiving episodic on demand factor replacement infrequently. Assam Journal of Internal Medicine 2020; 10(1): 27-31.

19. Shapiro AD, Donfield SM, Lynn HS, et al. Defining the impact of hemophilia: the Academic Achievement in Children with Hemophilia Study. Pediatrics 2001; 108: e105. www. doi: 10.1542/peds.108.6.e105.

20. Drake JH, Soucie MJ, Cutter SC, Forsberg AD, Baker JR, Riske B. High school completion rates among men with hemophilia. Am J Prev Med 2010; 38(4S): S489-S494. doi: 10.1016/j.amepre.2009.12.024.

21. Feldman BM, Pai M, Rivard GE, et al. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006; 4: 1228-36. 10.1111/j.1538-7836.2006.01953.x.

22. Verma SP, Dutta TK, Nalini P, et al. A randomized study of very low-dose factor VIII prophylaxis in severe haemophilia – a success story from a resource limited country. Haemophilia 2016; 22: 342-8. doi: 10.1111/hae.12838.

23. Sidarthan N, Sudevan R, Narayana Pillai V, et al. Low dose prophylaxis for children with haemophilia in a resource-limited setting in south India – a clinical audit report. Haemophilia 2017; 23: e382-e384. doi:10.1111/hae.13272.

24. Goudier E, Jouini L, Achour M, et al. Low dose prophylaxis in Tunisian children with haemophilia. Haemophilia 2017; 23: 77-81. doi: 10.1111/hae.13048.

25. Yao et al. The efficacy of recombinant FVIII low-dose prophylaxis in Chinese pediatric patients with severe hemophilia A: a retrospective analysis from the ReCARE study. Clin Appl Thromb Hemost 2017; 23: 851-8. doi: 10.1177/1076029616679507.

26. Sachdeva A, Gunasekaran V, Ramya HN, et al. Consensus statement of the Indian Academy of Pediatrics in diagnosis and management of hemophilia. Indian Pediatrics 2018; 55: 582-90. doi: 10.1007/s13312-018-1302-8.

27. World Federation of Hemophilia. Report on the Annual Global Survey 2011. December 2012. Available from (accessed 28 September 2020).

28. World Federation of Hemophilia. Report on the Annual Global Survey 20th Anniversary, 2018. October 2019. Available from (accessed 28 September 2020).

29. Kar A, Phadnis S, Dharmarajan S, Nakade J. Epidemiology & social costs of haemophilia in India. Indian J Med Res 2014; 140(1): 19-31.

HOW TO CITE THIS ARTICLE:
Dutta A, Boruah D, Dutta TS, Boruah A, Dhal BS. Improvement in school absence after factor replacement in students with haemophilia in Upper Assam, India. J Haem Pract 2020; 7(1): 136-142. https://doi.org/10.17225/jhp00166.